Wegovy vs. Mounjaro Side Effects: A Complete Comparison Guide

The Big Question: Potency vs. Tolerance

If you are choosing between Wegovy (semaglutide) and Mounjaro (tirzepatide), you probably already know that Mounjaro burns more fat. But there is one question every patient asks: "Which one is going to make me feel worse?"

It is a valid fear. No one wants to spend their weight loss journey stuck in the bathroom. The answer, backed by the latest 2026 data, might surprise you. Stronger does not always mean "sicker."

In our own clinic, the most common reason patients abandon treatment in the first month is gastrointestinal side effects — not cost, not injection anxiety. That is why our default protocol slows the standard titration schedule for new patients, and why I prefer to discuss expected side effects in detail before the first dose rather than after.

1. The Head-to-Head: Nausea & Vomiting

In clinical trials, researchers tracked how many patients felt sick on each drug. Here is the breakdown.

• Wegovy (semaglutide): In the STEP 1 trial, about 44% of patients reported nausea. ¹

• Mounjaro (tirzepatide): In the SURMOUNT-1 trial, nausea rates were generally lower, ranging from 25% to 33% depending on the dose. ²

Despite being more potent for weight loss, Mounjaro often causes LESS nausea than Wegovy.

Why? Mounjaro mimics two hormones (GLP-1 + GIP). The addition of GIP is believed to have an anti-emetic (anti-nausea) effect that counteracts the strong nausea caused by the GLP-1.

2. Common Side Effects Comparison Table

Here is what you can expect during the first month of treatment (the "adjustment phase").

3. The "Sulfur Burp" Phenomenon

Both medications slow down gastric emptying (how fast food leaves your stomach).

• The result: Food sits in your stomach longer and ferments. This causes burps that smell like rotten eggs (sulfur).

• Is it dangerous? No, but it is socially awkward.

• The fix: Avoid carbonated drinks and heavy red meat while on these drugs.

4. Serious Risks (Rare but Real)

Both drugs share the same "Black Box" warnings. These are rare (<1%) but you must know them: ³

• Pancreatitis: Severe pain in the upper stomach radiating to the back.

• Gallbladder issues: Rapid weight loss can cause gallstones.

• Thyroid tumors: Seen in rats, not confirmed in humans yet, but strictly forbidden if you have a family history of medullary thyroid cancer (MTC) or MEN2.

5. Which One Has Higher "Quit Rates"?

A good way to measure side effects is to see how many people quit the drug because they couldn't handle it.

• Wegovy: ~7% of patients in trials dropped out due to side effects.

• Mounjaro: ~4–7% dropped out (depending on dose).

Conclusion: The dropout rates are almost identical. This means that while Mounjaro is "stronger," it is just as tolerable as Wegovy for most people.

6. Expert Tip: How to Minimize Side Effects

Whether you choose Wegovy or Mounjaro, 90% of side effects are caused by user error.

• Don't rush the dose: If you feel sick, do not increase the dose next month. Stay on the lower dose until your body adapts.

• Stop eating at 70% full: The medication delays digestion. If you eat until you are "stuffed," you will vomit because there is nowhere for the food to go.

• Inject in the thigh: Anecdotal evidence suggests that injecting in the thigh (instead of the stomach) significantly reduces nausea for both drugs.

The Final Verdict

• Choose Mounjaro if: You are worried about nausea. Its dual mechanism often makes it "smoother" on the stomach despite being more effective.

• Choose Wegovy if: You have a sensitive bowel (prone to diarrhea), as Mounjaro's potency can sometimes be too stimulating for the gut.

Worried about side effects? At Phuket Weight Loss Center, we use a "micro-dosing" protocol to ensure you get the weight loss results without the nausea. Book a consultation with Dr. Akkavich today.

Related reading:

• Mounjaro vs. Wegovy: 2026 Guide →

• Why Muscle is Your "Metabolic Insurance" →

• Should You Start Just for Vacation? →

Tagged
side-effects nausea tolerability evidence-based

Medically reviewed
Siam Clinic Medical Team · Dr. Akkavich, M.D.
All clinical claims verified against peer-reviewed sources. How we write & cite →

References

• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

• U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information; Mounjaro and Zepbound (tirzepatide) prescribing information. Eli Lilly and Novo Nordisk. Accessed April 2026.